LakeShore Ev To Operating Cash Flow from 2010 to 2024

LSBPW Stock   0.04  0.01  33.33%   
LakeShore Biopharma EV To Operating Cash Flow yearly trend continues to be fairly stable with very little volatility. EV To Operating Cash Flow is likely to outpace its year average in 2024. EV To Operating Cash Flow is a valuation metric comparing LakeShore Biopharma's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows. View All Fundamentals
 
EV To Operating Cash Flow  
First Reported
2010-12-31
Previous Quarter
(0.60)
Current Value
(0.57)
Quarterly Volatility
0.97795171
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check LakeShore Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LakeShore Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.9 M, Interest Expense of 29.6 M or Selling General Administrative of 130.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Ptb Ratio of 0.0 or Days Sales Outstanding of 304. LakeShore financial statements analysis is a perfect complement when working with LakeShore Biopharma Valuation or Volatility modules.
  
Check out the analysis of LakeShore Biopharma Correlation against competitors.

Latest LakeShore Biopharma's Ev To Operating Cash Flow Growth Pattern

Below is the plot of the Ev To Operating Cash Flow of LakeShore Biopharma Co, over the last few years. It is a valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows. LakeShore Biopharma's EV To Operating Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LakeShore Biopharma's overall financial position and show how it may be relating to other accounts over time.
Ev To Operating Cash Flow10 Years Trend
Slightly volatile
   Ev To Operating Cash Flow   
       Timeline  

LakeShore Ev To Operating Cash Flow Regression Statistics

Arithmetic Mean0.94
Geometric Mean1.19
Coefficient Of Variation104.15
Mean Deviation0.84
Median1.51
Standard Deviation0.98
Sample Variance0.96
Range2.2129
R-Value(0.77)
Mean Square Error0.43
R-Squared0.59
Significance0.0009
Slope(0.17)
Total Sum of Squares13.39

LakeShore Ev To Operating Cash Flow History

2024 -0.57
2023 -0.6
2022 -0.7
2021 -0.63

About LakeShore Biopharma Financial Statements

LakeShore Biopharma investors use historical fundamental indicators, such as LakeShore Biopharma's Ev To Operating Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LakeShore Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EV To Operating Cash Flow(0.60)(0.57)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LakeShore Stock Analysis

When running LakeShore Biopharma's price analysis, check to measure LakeShore Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LakeShore Biopharma is operating at the current time. Most of LakeShore Biopharma's value examination focuses on studying past and present price action to predict the probability of LakeShore Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LakeShore Biopharma's price. Additionally, you may evaluate how the addition of LakeShore Biopharma to your portfolios can decrease your overall portfolio volatility.